Chromium picolinate and chromium histidinate protects against renal dysfunction by modulation of NF-B pathway in high-fat diet fed and Streptozotocin-induced diabetic rats

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Selcuk, Mustafa Yavuz ^a   Aygen, Bilge ^a   Dogukan, Ayhan ^a   Tuzcu, Zeynep ^a   Akdemir, Fatih ^a   Komorowski, James R ^b   Atalay, Mustafa ^c   Sahin, Kazim ^a,d  

^a FIRAT UNIVERSITY   (Turkey)

^b Nutrition 21 Inc   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d INONU UNIVERSITY   (Turkey)

Author keywords

Chromium picolinate histidinate; HNE; IB; Kidney; NF B; Nrf2

Indexed keywords

CHROMIUM; CHROMIUM HISTIDINATE; CHROMIUM PICOLINATE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET SUPPLEMENTATION; LIPID DIET; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

RATTUS; RATTUS NORVEGICUS;

EID: 84859417290     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-30     Document Type: Article

References (48)

1. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. Barnard RJ, Roberts CK, Varon SM, Berger JJ, J Appl Physiol 1998 84 1311 1315 9516198 (Pubitemid 28158697)
2. High-fat diet: modeling the metabolic disorders of human obesity in rodents. Buettner R, Schölmerich J, Bollheimer LC, Obesity 2007 15 798 808 10.1038/oby.2007.608 17426312 (Pubitemid 46740952)
3. Clinical studies on chromium picolinate supplementation in diabetes mellitus-a review. Broadhurst CL, Domenico P, Diabetes Technol Ther 2006 8 677 687 10.1089/dia.2006.8.677 17109600 (Pubitemid 44871498)
4. Diabetic neuropathy and oxidative stress. Pop-Busui R, Sima A, Stevens M, Diabetes Metab Res Rev 2006 22 257 273 10.1002/dmrr.625 16506271 (Pubitemid 44070502)
5. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Ceriello A, Diabetes Care 2003 26 1589 1596 10.2337/diacare.26.5.1589 12716823 (Pubitemid 36929196)
6. Oxidative stress as a therapeutic target in diabetes: revisiting the controversy. Wiernsperger NF, Diabetes Metab 2003 29 579 585 10.1016/S1262-3636(07)70072-1 14707886 (Pubitemid 38082159)
7. Oxidants, antioxidants and the ischemic brain. Warner DS, Huaxin S, Ines BH, J Exp Biol 2004 207 3221 3323 10.1242/jeb.01022 15299043 (Pubitemid 39275296)
8. Oxidative reactive species in cell injury: mechanisms in diabetes mellitus and therapeutic approaches. Fridlyand LE, Philipson LH, Ann NY Acad Sci 2005 1066 136 151 10.1196/annals.1363.019 16533924
9. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, Hofmann SM, Vlassara H, Shi Y, Circulation 2003 108 472 478 10.1161/01.CIR. 0000080378.96063.23 12860917 (Pubitemid 36935542)
10. Insulin resistance and chronic cardiovascular inflammatory syndrome. Fernandez-Real JM, Ricart W, Endocr Rev 2003 24 278 301 10.1210/er.2002-0010 12788800 (Pubitemid 36724371)
11. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D, Circulation 2002 106 2067 2072 10.1161/01.CIR.0000034509.14906.AE 12379575 (Pubitemid 35192812)
12. Oxidative stres and stress-activated signaling pathways: a unifying hypothesis of type-2 diabetes. Evans JL, Goldfine ID, Maddux BA, Grodsky GM, Endocr Rev 2002 23 599 622 10.1210/er.2001-0039 12372842 (Pubitemid 35191625)
13. Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Sriwijitkamol A, Christ-Roberts C, Berria R, Eagan P, Pratipanawatr T, DeFronzo RA, Mandarino LJ, Musi N, Diabetes 2006 55 760 767 10.2337/diabetes.55.03.06.db05-0677 16505240 (Pubitemid 43343233)
14. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE, Nat Med 2005 11 183 190 10.1038/nm1166 15685173 (Pubitemid 40321354)
15. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. Barnes PJ, Karin M, N Engl J Med 1997 336 1066 1071 10.1056/NEJM199704103361506 9091804 (Pubitemid 27163860)
16. Effect of early insulin therapy on nuclear factor-kappaB inflammatory pathway in liver of diabetic rat. Bi Y, Meng-yin C, Liang H, Sun WP, Chen X, Zhu YH, He XY, Yu QQ, Li M, Weng JP, Zhonghua Nei Ke Za Zhi 2009 48 17 22 19484971
17. Nutraceutical resources for diabetes prevention - an update. McCarty MF, Med Hypotheses 2005 64 151 158 10.1016/j.mehy.2004.03.036 15533633 (Pubitemid 39469256)
18. Effect of chromium picolinate on histopathological alterations in STZ and neonatal STZ diabetic rats. Shinde UA, Goyal RK, J Cell Mol Med 2003 3 322 329 (Pubitemid 37372052)
19. Effects of chromium picolinate on glucose uptake in insulin-resistant 3T3-L1 adipocytes involve activation of p38 MAPK. Wang YQ, Yao MH, J Nutr Biochem 2009 20 982 991 10.1016/j.jnutbio.2008.09.002 19195868
20. The effect of chromium on rat insulinoma cells in high glucose conditions. Kwon MJ, Chung HS, Yoon CS, Ko JH, Jun HJ, Kim TK, Lee SH, Ko KS, Rhee BD, Kim MK, Park JH, Life Sci 2010 87 401 404 10.1016/j.lfs.2010.08.001 20723550
21. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC, J Nutr 2002 132 1107 1114 12042418 (Pubitemid 34606436)
22. Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Sahin K, Onderci M, Tuzcu M, Ustundag B, Cikim G, Ozercan IH, Sriramoju V, Juturu V, Komorowski JR, Metabolism 2007 56 1233 1240 10.1016/j.metabol.2007.04.021 17697867 (Pubitemid 47225177)
23. Stability and absorption of chromium and absorption of chromium histidinate complexes by humans. Anderson RA, Polansky MM, Bryden NA, Biol Trace Elem Res 2004 101 211 218 10.1385/BTER:101:3:211 15564651 (Pubitemid 39612054)
24. Elucidating a biological role for chromium at a molecular level. Vincent JB, Acc Chem Res 2000 33 503 510 10.1021/ar990073r 10913239
25. Role of chromium in human health and in diabetes. Cefalu WT, Hu FB, Diabetes Care 2004 27 2741 2751 10.2337/diacare.27.11.2741 15505017 (Pubitemid 39441482)
26. Cellular chromium enhances activation of insulin receptor kinase. Wang H, Kruszewski A, Brautigan DL, Biochemistry 2005 44 8167 8175 10.1021/bi0473152 15924436 (Pubitemid 40776678)
27. Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S, Diabet Med 2000 17 684 685 11051290
28. Distribution and chromium-binding capacity of a low-molecular-weight, chromium-binding substance in mice. Yamamoto A, Wada O, Ono TJ, Inorg Biochem 1984 22 91 102 10.1016/0162-0134(84)80018-5 (Pubitemid 15215239)
29. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Davis CM, Vincent JB, Biochemistry 1997 36 4382 4385 10.1021/bi963154t 9109644 (Pubitemid 27180283)
30. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM, Metabolism 2000 49 1390 1394 10.1053/meta.2000.17721 11092499
31. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A, Koya D, J Am Soc Nephrol 2007 18 2715 2723 10.1681/ASN.2007010089 17855643 (Pubitemid 47531198)
32. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Farombi EO, Shrotriya S, Na HK, Food Chem Toxicol 2008 46 1279 1287 10.1016/j.fct.2007.09.095 18006204 (Pubitemid 351258204)
33. Protein measurement with the folin phenol reagent. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, J Biol Chem 1951 193 165 175
34. SAS User's Guide: Statistics (Version 9th.). SAS, Statistical Analysis SystemInstitute Inc., Cary, NC, USA 2002
35. Chromium chloride inhibits oxidative stress and TNF- secretion caused by exposure to high glucose in cultured monocytes. Jain SK, Kannan K, Biochem Biophys Res Commun 2001 289 687 691 10.1006/bbrc.2001.6026 11726202 (Pubitemid 33152288)
36. Chromium chloride inhibits TNF- and IL-6 secretion in isolated human blood monoclear cells exposed to high glucose. Jain SK, Lim G, Horm Metab Res 2006 38 60 62 10.1055/s-2006-924981 16477544
37. Effect of chromium niacinate and chromium picolinate supplementation on lipid peroxidation, TNF-a, IL-6, CRP, glycated hemoglobin, triglycerides and cholesterol levels in blood of streptozotocin-treated diabetic rats. Jain SK, Rains JL, Croad JL, Free Radic Biol Med 2007 43 1124 1131 10.1016/j. freeradbiomed.2007.05.019 17854708 (Pubitemid 47374434)
38. Suppression of NF- signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Kuhad A, Bishnoi Mahendra, Tiwari Vinod, Chopra Kanwaljit, Pharmacol Biochem Behav 2009 92 251 259 10.1016/j.pbb.2008.12.012 19138703
39. Effects of different chromium compounds on blood pressure and lipid peroxidation in spontaneously hypertensive rats. Preuss HG, Grojec PL, Lieberman S, Anderson RA, Clin Nephrol 1997 47 325 330 9181280 (Pubitemid 27230630)
40. Effects of chromium histidinate on renal function, oxidative stress, and heat-shock proteins in fat-fed and streptozotocin-treated rats. Dogukan A, Tuzcu M, Juturu V, Cikim G, Ozercan I, Komorowski J, Sahin K, J Ren Nutr 2010 20 112 120 10.1053/j.jrn.2009.04.009 19616452
41. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Figueroa-Romero C, Sadidi M, Feldman EL, Rev Endocr Metab Disord 2008 9 301 314 10.1007/s11154-008-9104-2 18709457
42. Improvement of inflammatory responses associated with NF-kB pathway in kidneys from diabetic rats. Chen L, Zhang J, Zhang Y, Wang Y, Wang B, Inflamm Res 2008 57 199 204 10.1007/s00011-006-6190-z 18465086
43. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Ma Q, Battelli L, Hubbs AF, Am J Pathol 2006 168 1960 1974 10.2353/ajpath.2006.051113 16723711 (Pubitemid 43825316)
44. Activation of Nrf2 in defense against cadmium-induced oxidative stress. He X, Chen MG, Ma Q, Chem Res Toxicol 2008 21 1375 1383 10.1021/tx800019a 18512965
45. Resveratrol protects diabetic kidney by attenuating hyperglycemia- mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Palsamy P, Subramanian S, Biochim Biophys Acta 2011 1812 719 731 21439372
46. Impact of chromium histidinate on high fat diet induced obesity in rats. Tuzcu M, Sahin N, Orhan C, Agca CA, Akdemir F, Tuzcu Z, Komorowski J, Sahin K, Nutr Metab (Lond) 8 8 28
47. 4-Hydroxy-2-Nonenal Induces Mitochondrial Dysfunction and Aberrant Axonal Outgrowth in Adult Sensory Neurons that Mimics Features of Diabetic Neuropathy. Akude E, Zherebitskaya Elena, Subir K, Chowdhury Roy, Girling Kimberly, Fernyhough Paul, Neurotox Res 2010 17 28 38 10.1007/s12640-009-9074-5 19557324
48. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in Apo E-deficient mice. Pratic D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA, Nat Med 1998 4 1189 1192 10.1038/2685 9771755 (Pubitemid 28468835)